EGTX highlights tiratricol progress ahead of near-term PDUFA
The company is advancing tiratricol for MCT8 deficiency and points to robust clinical data, expanding presence, and an upcoming PDUFA date.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.